

The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research: A Workshop

Keck Center of the National Academy of Sciences, 500 Fifth St. NW Washington, DC

Washington, DC		
	June 8th, 2015	
7:30 am	Registration and Breakfast	
8:00 am	Welcome from the National Cancer Policy Forum	
	Overview of the Workshop	
	Michael Kastan (Duke)	
	Planning Committee Chair	
8:15	Session 1: Overview and value of trials that include pets in translational cancer research	
	Moderator: Michael Kastan, Duke University	
	Overview of current challenges and opportunities in oncology drug development	
	Lee Helman, National Cancer Institute	
	Consider and limitarious of the different and distinct and the	
	Strengths and limitations of traditional pre-clinical models Parenty Toichen National Concern Institute	
	Beverly Teicher, National Cancer Institute	
	Advantages and experiences with trials that include animal patients	
	Chand Khanna, National Cancer Institute	
	Chand Khaima, Ivational Cancer Institute	
	Group Discussion	
10:10	Break	
10:20	Session 2: Canine tumor biology and genomics informing cancer drug development	
	Moderator: Deborah Knapp, Purdue University	
	The current state of canine tumor genetics and scientific limitations	
	Heidi Parker, National Institutes of Health/National Human Genome Research Institute	
	Use and availability of canine cancer tissue banks in translational research	
	Matthew Breen, North Carolina State University	
	Genomic resources for canine cancer research	
	Jessica Alföldi, Broad Institute of MIT and Harvard	
	Biology and informatics needs	
	Jeff Trent, TGEN	
	Jen Hent, 1GEN	
	Group Discussion	
12:15 pm	Lunch Break	
1:00 pm	Session 3: Effectively integrating biomarkers into study designs	
	Moderator: Carl Barrett, AstraZeneca	
	Opportunities for preclinical evaluation of novel therapies	
	Timothy Fan, University of Illinois at Urbana-Champaign	
	PK assessment	
	Dan Gustafson, Colorado State University	
	PD and potential predictive biomarkers	
	Doug Thamm, Colorado State University	
	Group Discussion	
2.30 nm	Session 4: Effectively integrating imaging technologies into study designs	
2:30 pm	Session 4: Effectively integrating imaging technologies into study designs Moderator: Peter Choyke, National Cancer Institute	
	120ueruor. 1 cici Choyke, ivalional Cancer institute	
	Role of trials that include pets in the development of new imaging modalities	
	Peter Choyke, National Cancer Institute	
	1 Caryany I invavana Cuarce amunitare	

	MDY
	MRI spectroscopy Mark Dewhirst, Duke University
	Mark Dewniest, Dake Chrystoly
	Group Discussion
3:30 pm	Break
3:45 pm	Session 5: Mechanisms for Comparative Oncology Trials Moderator: Lou DeGennaro, Leukemia and Lymphoma Society
	Single-institution studies Cheryl London, Ohio State University
	Multi-institution studies Amy LeBlanc, National Cancer Institute
	Group Discussion
4:45 pm	Wrap up Day 1
5:15 pm	Reception – 3 rd Floor Atrium
	June 9th, 2015
7:30 am	Registration and Breakfast
8:00 am	Session 6: Addressing the needs of pet animals and their owners Moderator: Michael Lairmore, University of California—Davis
	Trial design and appropriate oversight David Vail, University of Wisconsin
	Best-practices for conduct of clinical trial for animal patients Rod Page, Colorado State University Patricia Olson, Independent Advisor on Animal Health/Welfare
	Group Discussion
9:45 am	Break
10:00 am	Session 7: The status of comparative oncology in drug development <i>Moderator:</i> Perry Nisen, Sanford-Burnham Research Institute
	Panelists: Anne Keane, Achaogen
	Wendy Levin, MEI Pharma
	Daniel Tumas, Gilead Sciences, Inc. John Leighton, Food and Drug Administration
	Group Discussion
11:30 pm	Workshop Wrap Up—Deborah Knapp, Purdue University & Len Lichtenfeld, American Cancer Society
12:00 pm	Adjourn
12.00 pm	114jvui